{"id":"sandostatin-injection","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Abdominal pain or discomfort"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-15","effect":"Hyperglycemia or hypoglycemia"},{"rate":"15-30","effect":"Gallstone formation (cholelithiasis)"},{"rate":"5-10","effect":"Injection site pain or reaction"}]},"_chembl":{"chemblId":"CHEMBL408687","moleculeType":"Small molecule","molecularWeight":"1005.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and normal endocrine tissues. This binding suppresses the release of excessive hormones and growth factors, reducing symptoms associated with hormone-secreting tumors and controlling hormone-related complications. It also has anti-proliferative effects on some neuroendocrine tumors.","oneSentence":"Sandostatin (octreotide) is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells to inhibit the secretion of growth hormone, insulin, and other hormones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:50.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly (growth hormone-secreting pituitary adenoma)"},{"name":"Variceal bleeding in portal hypertension"},{"name":"Carcinoid syndrome"},{"name":"VIPoma (vasoactive intestinal peptide-secreting tumor)"},{"name":"Gastrinoma"},{"name":"Neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":226},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":"Neuroendocrine Tumors","enrollment":309},{"nctId":"NCT06080204","phase":"NA","title":"Real-world Study on Adjuvant Octreotide Therapy in pNETs","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2008-03","conditions":"Pancreatic Neuroendocrine Tumor G2","enrollment":411},{"nctId":"NCT05761431","phase":"PHASE1","title":"A Single-dose Study of Octreotide Injection in Healthy Adult Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-03-02","conditions":"Acromegaly","enrollment":56},{"nctId":"NCT01613495","phase":"NA","title":"Ghrelin Suppression by Octreotide in Prader-Willi","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2005-08","conditions":"Prader Willis Syndrome","enrollment":2},{"nctId":"NCT03791736","phase":"NA","title":"Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2016-07-06","conditions":"Breast Cancer, Lymphocele","enrollment":4},{"nctId":"NCT04552847","phase":"PHASE2, PHASE3","title":"Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-10-07","conditions":"Neuroendocrine Tumors","enrollment":85},{"nctId":"NCT00171730","phase":"PHASE2","title":"An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08-24","conditions":"Acromegaly","enrollment":30},{"nctId":"NCT00092287","phase":"PHASE3","title":"Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","status":"TERMINATED","sponsor":"Ipsen","startDate":"2004-07","conditions":"Malignant Carcinoid Syndrome","enrollment":4},{"nctId":"NCT02299089","phase":"PHASE2","title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2015-01","conditions":"Acromegaly, Neuroendocrine Tumors","enrollment":12},{"nctId":"NCT03031535","phase":"PHASE1","title":"Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dauntless Pharmaceuticals","startDate":"2017-01","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT01618513","phase":"PHASE4","title":"Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-06","conditions":"Acromegaly","enrollment":84},{"nctId":"NCT02195635","phase":"PHASE1","title":"Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-07","conditions":"Drug Interactions","enrollment":24},{"nctId":"NCT01121939","phase":"PHASE2","title":"Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-05","conditions":"Neuroendocrine Carcinoma","enrollment":43},{"nctId":"NCT02012166","phase":"PHASE1","title":"A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT02427295","phase":"PHASE4","title":"Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-03","conditions":"Acromegaly","enrollment":1},{"nctId":"NCT00987168","phase":"PHASE2","title":"Sandostatine® LP and Hyperinsulinism","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-05","conditions":"Congenital Hyperinsulinism","enrollment":10},{"nctId":"NCT00426153","phase":"PHASE2, PHASE3","title":"Octreotide in Severe Polycystic Liver Disease","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly","enrollment":42},{"nctId":"NCT00332696","phase":"PHASE2","title":"Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Octreotide LAR","Octreotide","Octreo","Lanreotide"],"phase":"marketed","status":"active","brandName":"Sandostatin ® injection","genericName":"Sandostatin ® injection","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sandostatin (octreotide) is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells to inhibit the secretion of growth hormone, insulin, and other hormones. Used for Acromegaly (growth hormone-secreting pituitary adenoma), Variceal bleeding in portal hypertension, Carcinoid syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}